Pulse Biosciences Files 510(k) Submission with US FDA for its CellFX nsPFA Cardiac Clamp
Portfolio Pulse from Benzinga Newsdesk
Pulse Biosciences, Inc. has filed a 510(k) submission with the FDA for its CellFX nsPFA Cardiac Clamp, a technology aimed at treating atrial fibrillation.
January 02, 2024 | 1:01 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Pulse Biosciences has submitted a 510(k) for its CellFX nsPFA Cardiac Clamp, indicating progress in its regulatory pathway and potential market expansion.
The 510(k) submission is a critical regulatory step for Pulse Biosciences, signaling the company's advancement towards commercialization of its CellFX nsPFA technology. If approved, it could lead to increased adoption and revenue growth. The news is likely to be viewed positively by investors, as it demonstrates progress in the company's product pipeline.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100